Navigation Links
Thera Max® Cold and Flu Brand Receives Great Benefits from Its Ongoing Social Media Marketing Awareness Program
Date:2/29/2012

NEW YORK, Feb. 29, 2012 /PRNewswire/ -- TheraBiogen, Inc. (OTC BB: TRAB), a manufacturer and distributor of homeopathic  nasal sprays for aiding in the relief of allergies, cold and flu symptoms and migraine headaches, announced today the benefits its Thera Max® Cold and Flu brand is receiving through the ongoing Social Media campaign. 

The Company is taking its new homeopathic product, Thera Max® Cold and Flu into the social media arena in a very aggressive fashion. The campaign was launched on a billboard in Times Square, with interview testimonials posted on YouTube and receiving over 40,000 views to date. 

Additionally, CEO Kelly Hickel, has begun a radio media tour that has attracted editorial interest and the company believes that a number of other opportunities will arise from these efforts.  In October, the product was distributed to two large retail pharmacy chains and the Company intends to build upon this momentum.

Thera Max® offers a better alternative to cold and flu medications because it doesn't contain Zinc, which has been shown to cause adverse side-effects especially with nasal sprays.  Thera Max® Cold and Flu is an all-natural, non-addictive, over the counter cold and flu relief agent which aids in relief to cold and flu sufferers.

TheraBiogen, Inc., creator of TheraMax® Cold and Flu has a pipeline of products under development, including allergy, sore throat and migraine remedies. The growing interest in safe, homeopathic products is driving the continued development of the TheraBiogen lineup.

The product is currently sold in over 12,000 locations including Food Lion and various other retailers.  With the addition of the two large retailers, the Company intends to become a leading competitor in the world of over the counter medications for cold and flu symptoms.

The product is a homeopathic product of ingredients pre- approved on the HPUS website. Independent studies suggest the product aids in the temporary relief of common cold and flu ailments such as sneezing, runny nose, itch-watery eyes, nasal congestion and sinus pressure and can aid in the prevention if used correctly.

Flu commercials and Times Square videos may be viewed on the Thera Max® YouTube page at http://www.youtube.com/user/TheraMaxRelief

Thera Max® Cold and Flu is an all-natural, non-zinc, non-addictive, over-the-counter cold and flu relief agent.  Over 50 million Americans contract the flu each year and consumer demand for a homeopathic, non-zinc remedy is a 2.5 billion dollar market according to research studies.

Thera Max® is available for purchase in over twelve thousand locations including Rite-Aid, Food Lion, Hannaford Supermarkets, Discount Drug Marts and Big Y Supermarkets as well as two of the three largest drug retailers.  For more information on Thera Max® visit our website at www.theramaxrelief.com, our Facebook page at http://www.facebook.com/#!/TheraMaxNasalSpray  or follow us on Twitter at http://twitter.com/theramaxrelief

 About TheraBiogen, Inc.TheraBiogen is a manufacturer and distributor of homeopathic nasal sprays for aiding in the relief of allergies, cold and flu symptoms and migraine headaches. The products are made from natural, homeopathic ingredients and contain no zinc, which has been identified as potentially causing nasal problems in other similar products on the market. For further information please visit www.theramaxrelief.com.

Safe Harbor Statement

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21 E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that these forward-looking statements involve uncertainties and risk that could cause actual performance and results of operations to differ materially from those anticipated. These risks are set forth in the Company's most recently filed form 10-K and Form 10-Q reports. TheraBiogen, Inc. assumes no obligation to update the statements contained in this release except as required by applicable securities laws disclosure rules.Company Contact:Public Relations Contact:Investor Contact:TheraBiogen, Inc.

Megan Megale

Boutcher & BoutcherKelly T. Hickel, CEO

Megale Public Relations 

Aimee Boutcher732-294-8705

703-625-8093

973-239-2878kthickel@therabiogen.com

mmegale@megalepr.com

Aboutcher@therabiogen.com 


'/>"/>
SOURCE TheraBiogen, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Nektar Therapeutics Announces Agreement to Sell CIMZIA® and MIRCERA® Royalties to Royalty Pharma for $124 Million
2. Varian Medical Systems Receives FDA 510(k) Clearance for Use of Transponder to Monitor Motion During Radiotherapy Anywhere in Body
3. New Therapy Program Allows Doctors to Prescribe Computer Games on iPad to Treat Visual Impairment
4. JARVIK HEART Announces FDA Conditional Approval of Trial Using the Jarvik 2000® Heart for Destination Therapy
5. Octapharma USA Submits BLA for octaplasLG®, a Therapy Targeting Adverse Transfusion Events
6. Generex Subsidiary Antigen Express to Present at Prestigious Cancer Immunotherapy Summit
7. Ameritox Supports New Expert Consensus Recommendations For Patients on Long-Term Opioid Therapy
8. Study Links the Risk of Hypogonadism in Men to Long Acting Opioids in Patients Using Daily Opioid Therapy for Chronic Noncancer Pain
9. Brainlab Partners With Radion to Integrate VoyantLink Image Sharing Into One Streamlined Solution for Radiation Therapy Centers
10. Anthera Pharmaceuticals to Present at the Citi Global Health Care Conference
11. Halozyme Therapeutics to Present at the CITI 2012 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Key Pharma News Issue 52" report to their offering. ... need in influenza treatment creates a favourable commercial environment for ... and growing patient base that will serve to drive considerable ... flu vaccine would serve to cap sales considerably, but development ...
(Date:6/23/2016)... Calif. , June 23, 2016 ... CST on Thursday, July 7, 2016 , , , , ... ) , , , , EXPERT PANELISTS:  , , ... Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar ... The global pharmaceutical industry is witnessing an exceptional ...
Breaking Medicine Technology:
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... ... to fertility once they have been diagnosed with endometriosis. These women need a ... they also require a comprehensive approach that can help for preservation of fertility ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/25/2016)... ... ... Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and Mental ... exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took place ... BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive an ...
Breaking Medicine News(10 mins):